Abzena

Looking to simplify & secure your bioconjugate’s supply chain? If so, then schedule a meeting with our drug development experts at CPHI in Frankfurt to discover how Abzena can streamline your development pathway. With over 24 years of experience, 3000+ linker-payloads designed, and 2000+ conjugates developed, we have the technical know-how, next-gen technologies, and state-of-the-art facilities needed to successfully deliver your ADC, AOC, or RDC from early R&D through to commercial launch. Schedule a meeting with us in stand #6.1B26 to explore how our fully integrated end-to-end CDMO+CRO services can help get your innovation to patients in need faster: https://lnkd.in/gJ24WGzQ We look forward to connecting with you in Frankfurt! #Bioconjugation #CPHI #CDMO #CRO #SupplyChain #DrugDevelopment

Process development is a critical step in biological drug development that ensures consistent product quality, safety, and scalability. However, biologic therapeutics are inherently complex and present unique challenges, requiring specialized expertise and advanced technologies to successfully progress towards GMP manufacturing. At Abzena, we offer comprehensive process development services tailored to the specific needs of your therapeutics, including: -Upstream Cell Culture Support: to enhance cell growth, productivity, & product quality -Downstream Purification Support: to ensure high purity & yield while maintaining critical quality attributes -Advanced Analytical Method & Product Characterization: state-of-the-art capabilities that support every stage of development -Regulatory Compliance and Quality Assurance: we adhere to the highest standards of compliance & quality across our facilities, systems, and processes. Discover how we can help you navigate the complexities of process development so that you can focus on bringing innovative therapies to patients faster: https://lnkd.in/eFyKsNYF #ProcessDevelopment #CDMO #CRO #Biologics #LargeMolecules

Cell line development (CLD) shouldn't slow down your biologic's development timeline. Join CLD experts from Abzena, Revvity, and ProteoNic on Oct. 21st for a live Q&A panel-style webinar, where we’ll explore how flexible, next-gen cell line platforms deliver rapid timelines, higher productivity, and regulatory confidence- offering developers a de-risked and streamlined path to the clinic. From integrated analytics to product quality and process efficiency, our panel will share insights on how to tackle the biggest challenges that you may be facing in CLD today, so that you can focus on getting to your next target inflection point faster. Register here: https://lnkd.in/eWbAfskb #CellLineDevelopment #Biologics #Webinar #CRO #CDMO #DrugDevelopment

The success of many cancer therapeutics lies in their ability to induce ADCC, ADCP and CDC against specific targets - making appropriate assessment even more crucial before progressing a drug into the clinic. At Festival of Biologics in Basel earlier this month, our Sr. Manager of Bioassay, Rosa Gonzàlez Serrano, presented a poster on the key aspects for developing successful Fc effector functional assays, the benefits and challenges of a panel of assay formats for different purposes and options for choosing the most suitable target cell lines, effector cells and appropriate controls. Interested in learning more about our comprehensive suite of assays that can de-risk your antibodies, Fc fusions or ADC products, click here to get a copy of the poster: https://lnkd.in/gfxJXqNY #Bioassay #EffectorFunction #CRO #DrugDevelopment #Biologics

Antibody-Oligonucleotide Conjugates (AOCs) have the potential to transform therapies. However, the development of AOCs is far from straightforward. While AOCs & ADCs share structural similarities, their development processes differ significantly due to the complexity of oligo payloads in AOCs. These differences present distinct technical and analytical challenges that developers must address. In our latest article in Outsourced Pharma, our AOC experts, Jeffrey C. Mocny, Ph.D. & Stephen Verespy discuss the scientific ingenuity necessary to develop these complex molecules and the regulatory considerations to ensure a smooth pathway to approval. Access the article to get a better understanding of the intricate chemistry and technical expertise required to successfully develop and manufacture these complex molecules: https://lnkd.in/g2aCNXFG #AOCs #Bioconjugates #CDMO #CRO #DrugDevelopment

Identifying a partner that can handle the early design of your antibody - while generating the high-quality data needed for confident decision-making - is key for your biologics’ success.     At Abzena’s Cambridge, UK site, we bring together integrated capabilities in protein engineering, bioassay & immunogenicity, cell line development, formulation, and advanced analytics, all in one place. By combining expertise in complex biologics and bioconjugates (including ADCs and AOCs) with robust assessment platforms, we help you de-risk and streamline your path to IND and accelerate the journey from lead identification to clinical success. Discover how our Cambridge facility can support your early-stage program so that you start smart and finish fast: https://lnkd.in/esbqFavz   #DrugDevelopment #CRO #CDMO #Biologics #R&D

Addressing immunogenicity early in the development process minimizes costly setbacks, accelerates time to market, and enhances a therapeutic program’s overall success. At Abzena, our robust suite of assays, combined with our extensive experience and innovative approach, ensures that your biologic candidates are thoroughly assessed for immunogenic potential, facilitating smoother regulatory pathways and enhancing clinical outcomes.   Whether it's generating risk assessment data or helping to facilitate lead candidate selection, we have the capabilities to help you better understand your drug candidate. Access our informational brochure to discover what sets our industry-leading immunogenicity services apart today: #CRO #Immunogenicity #Bioassay #Biologics #DrugDevelopment 

Our latest cell line development whitepaper explores two primary approaches to generating stable cell lines – random integration and semi-targeted (or transposase) integration, and how they can differ in their impact on expression, variability, scalability, and regulatory approval. Key Takeaways include: - Random integration can match or exceed semi-targeted integration in productivity, stability, and process robustness.  - Random integration offers flexibility and lower complexity, avoiding reliance on proprietary transposase systems.  - With optimized vectors and screening, Random integration delivers high-quality clones efficiently.  - Semi-targeted methods may not always justify their cost or complexity.  - Drug developers should choose integration strategies based on context, not hype Rather than declaring one approach categorically better, this whitepaper advocates for context-driven CLD decisions, empowering the drug developer to reconsider assumptions and embrace the method best suited for their program. Access the whitepaper to determine which CLD approach is best for your molecule, timeline, and budget: https://lnkd.in/gsHyyE7t #CellLineDevelopment #CRO #CDMO #DrugDevelopment #Biologics

ICYMI: At BioProcess International East in Boston last month, our head of Cell Line Development, Brett Verstak, presented a talk entitled, “Leveraging Analytics to Ensure Stable & Scalable Cell Lines.” The presentation detailed how our newly enhanced AbZelectPRO™ CHO-K1 & GS Knockout CLD platforms leverage a comprehensive, in-house analytics portfolio to simplify the IND application process and deliver customer therapeutic proteins successfully to clinical phases in an accelerated timeframe. Access his on-demand presentation to learn how our streamlined CLD platforms can get you into the clinic faster: https://lnkd.in/eHHp2fyJ #CellLineDevelopment #AbZelectPRO #CRO #CDMO #BioProcessInternational #BPIConf #BPI #DrugDevelopment

Are you looking for your next career opportunity? Come grow with Abzena! We have exciting roles across several of our global teams that may be the perfect fit for your next move. When you bring your talents to Abzena, you’ll be able to contribute to some of the most innovative development programs anywhere - collaborating with the brightest minds, sharing ideas, advancing knowledge, and delivering real-world results. Whether you’re interested in a scientific, commercial, or operational role, we welcome you to check out our open positions today by visiting here: https://lnkd.in/eQmJJu_Z #AbzenaCareers #CDMO #CRO #WeAreHiring #DrugDevelopment